Department of Ophthalmology, Asociación para Evitar Ceguera en México, Hospital Luis Sanchez Bulnes IAP, Mexico City, Mexico.
Br J Ophthalmol. 2013 Jul;97(7):816-9. doi: 10.1136/bjophthalmol-2012-302276. Epub 2012 Dec 8.
To evaluate ocular outcome in premature infants treated with intravitreal ranibizumab injections for retinopathy of prematurity (ROP) over a period of 3 years.
An interventional case series. Premature infants with high-risk prethreshold or threshold ROP with plus disease received an off label monotherapy with intravitreal injections of ranibizumab. The primary outcome was treatment success defined as regression of neovascularisation (NV) and absence of recurrence. The secondary outcomes were ocular and systemic adverse events and visual acuity.
Six eyes were included in the study and treated with intravitreal injections of ranibizumab. All showed complete resolution of NV after a single injection. The anti-angiogenic intravitreal injections allowed for continued normal vessel growth into the peripheral retina, without any signs of disease recurrence or progression during the follow up period. No ocular or systemic adverse effects were observed.
Three years of follow up in a small series suggest that intravitreal ranibizumab injections for ROP result in apparently preserved ocular outcome. Further large scale studies are needed to address the long-term safety and efficacy.
评估早产儿接受玻璃体内雷珠单抗注射治疗早产儿视网膜病变（ROP）3 年的眼部结局。
一项干预性病例系列研究。患有高危未阈值或阈值 ROP 伴 plus 病的早产儿接受了雷珠单抗玻璃体内注射的标签外单药治疗。主要结局是治疗成功定义为新生血管（NV）消退且无复发。次要结局是眼部和全身不良事件以及视力。
本研究纳入 6 只眼，并接受玻璃体内雷珠单抗注射治疗。单次注射后，所有眼的 NV 均完全消退。抗血管生成的玻璃体内注射允许血管继续正常生长到周边视网膜，在随访期间没有疾病复发或进展的迹象。未观察到眼部或全身不良反应。
小系列 3 年随访表明，玻璃体内雷珠单抗注射治疗 ROP 可明显保留眼部结局。需要进一步的大规模研究来解决长期安全性和疗效问题。
